Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
Cayman IslandsIPO:
23 September 2023Website:
http://www.adlainortye.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 18 Nov 2024 21:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
ANL Latest News
Adlai Nortye Ltd. Sponsored ADR (ANL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, recently announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery). This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E receptor 4 (“EP4”) antagonist, with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: ‘TNT') (“CRT”) for the treatment of rectal cancer. The study has been developed and is being led by the Cancer Research (“CRUK”) Clinical Trials Unit (“CTU”) at the University of Leeds, with clinical leadership teams from consultant oncologists Prof Simon Gollins and Prof Mark Saunders.
This is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have fared in comparison to their industry in the current year.
Adlai Nortye Ltd. Sponsored ADR (ANL) and Elevance Health (ELV) have outperformed their sector year-to-date.
The third quarter wrapped up with four IPOs and eight pipeline additions. Eight issuers submitted initial filings this past week. The October IPO market looks like it will be off to a quiet start, with no IPOs currently scheduled for the week ahead.
Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time through the August break, the SPAC market is churning out deals. Three IPOs are currently scheduled to list in the week ahead, although other small issuers may join the calendar during the week.
Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials for solid tumors and head and neck squamous cell cancer. The global market for head and neck cancer treatments is expected to reach $3.5 billion by 2030.
Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbol “ANL”.
What type of business is Adlai Nortye American Depositary Shares?
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
What sector is Adlai Nortye American Depositary Shares in?
Adlai Nortye American Depositary Shares is in the Healthcare sector
What industry is Adlai Nortye American Depositary Shares in?
Adlai Nortye American Depositary Shares is in the Biotechnology industry
What country is Adlai Nortye American Depositary Shares from?
Adlai Nortye American Depositary Shares is headquartered in Cayman Islands
When did Adlai Nortye American Depositary Shares go public?
Adlai Nortye American Depositary Shares initial public offering (IPO) was on 23 September 2023
What is Adlai Nortye American Depositary Shares website?
https://www.adlainortye.com
Is Adlai Nortye American Depositary Shares in the S&P 500?
No, Adlai Nortye American Depositary Shares is not included in the S&P 500 index
Is Adlai Nortye American Depositary Shares in the NASDAQ 100?
No, Adlai Nortye American Depositary Shares is not included in the NASDAQ 100 index
Is Adlai Nortye American Depositary Shares in the Dow Jones?
No, Adlai Nortye American Depositary Shares is not included in the Dow Jones index
When was Adlai Nortye American Depositary Shares the previous earnings report?
No data
When does Adlai Nortye American Depositary Shares earnings report?
The next expected earnings date for Adlai Nortye American Depositary Shares is 29 November 2024